Moxifloxacin

Generic Name: Moxifloxacin

Brand Names: Avelox, Moxeza, Vigamox

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₄FN_₃O_₄

CAS Number: 151096-09-2

Unique Ingredient Identifier: U188XYD42P

Background: Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.

Indication: For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).

Associated Conditions: Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections

Associated Therapies: -

Clinical Trials

Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy Subjects

Phase 1

Completed

Conditions: HIV/AIDS

Interventions: Drug: Moxifloxacin
Drug: Placebo
Drug: Efavirenz

First Posted Date: 2014-06-17

Last Posted Date: 2015-09-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 58

Registration Number: NCT02164812

Locations: 🇺🇸
Parexel International - Baltimore Epcu, Baltimore, Maryland, United States

A Thorough QT Study of Telotristat Etiprate

Phase 1

Completed

Conditions: QT Interval

Interventions: Drug: Telotristat etiprate
Drug: Moxifloxacin
Drug: Placebo

First Posted Date: 2014-06-04

Last Posted Date: 2014-09-08

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 48

Registration Number: NCT02155205

Locations: 🇺🇸
Lexicon Investigational Site, Evansville, Indiana, United States

A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-54861911-Therapeutic Dose
Drug: JNJ-54861911 - Supratherapeutic Dose
Drug: JNJ-54861911-Matched Placebo
Drug: Moxifloxacin
Drug: Moxifloxacin Matched Placebo

First Posted Date: 2014-06-02

Last Posted Date: 2014-11-24

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 64

Registration Number: NCT02152332

Race Difference Moxifloxacin-induced QT Prolongation Between Healthy Chinese and Caucasian Volunteers

Phase 1

Conditions: Cardiac Toxicity

Interventions: Drug: Moxifloxacin

First Posted Date: 2014-04-21

Last Posted Date: 2014-04-21

Lead Sponsor: Haiyan Li

Target Recruit Count: 80

Registration Number: NCT02119091

Locations: 🇺🇸
Spaulding Clinical Research LLC, West Bend, Wisconsin, United States
🇨🇳
Peking University Third Hospital Clinical Trial Center, Beijing, Beijing, China

Improving Retreatment Success (IMPRESS)

Phase 1

Completed

Conditions: Recurrent Tuberculosis

Interventions: Drug: moxifloxacin

First Posted Date: 2014-04-15

Last Posted Date: 2019-08-05

Lead Sponsor: Centre for the AIDS Programme of Research in South Africa

Target Recruit Count: 197

Registration Number: NCT02114684

Locations: 🇿🇦
CAPRISA eThekwini Clinical Research Site (eCRS), Durban, KwaZulu Natal, South Africa

A 2-Part Study to Evaluate the Safety of Supra-Therapeutic Doses of RO4602522 and to Investigate the Effect of RO4602522 on the QTc Interval

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: RO4602522
Other: Placebo RO4602522
Other: moxifloxacin placebo
Drug: moxifloxacin

First Posted Date: 2014-04-04

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 203

Registration Number: NCT02104648

Comparisons of Intravenous Ceftriaxone With Intravenous Moxifloxacin in ERCP

Phase 2

Completed

Conditions: Cholangitis

Interventions: Drug: ceftriaxone
Drug: Moxifloxacin

First Posted Date: 2014-03-28

Last Posted Date: 2016-02-24

Lead Sponsor: Kangbuk Samsung Hospital

Target Recruit Count: 86

Registration Number: NCT02098486

Locations: 🇰🇷
Sungkyunkwan University Kangbuk Samsung Hospital, Seoul, Korea, Republic of

Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy Subjects

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: BMS-791325
Drug: Placebo matching BMS-791325
Drug: Moxifloxacin

First Posted Date: 2014-03-12

Last Posted Date: 2014-07-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 59

Registration Number: NCT02084953

Locations: 🇺🇸
Ppd Development, Llc, Austin, Texas, United States

A Thorough Corrected QT Interval Trial

Phase 1

Completed

Conditions: Dyslipidemia

Interventions: Drug: K-877 Low Dose
Drug: Moxifloxacin
Other: Placebo
Drug: K-877 High Dose

First Posted Date: 2014-02-27

Last Posted Date: 2015-04-10

Lead Sponsor: Kowa Research Institute, Inc.

Target Recruit Count: 56

Registration Number: NCT02073084

A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: placebo
Drug: semaglutide
Drug: moxifloxacin

First Posted Date: 2014-02-17

Last Posted Date: 2018-06-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 168

Registration Number: NCT02064348

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy